Amyloidosis: Find a Clinical Trial
The Herbert Irving Comprehensive Cancer Center is a national leader in research on amyloidosis. The Program’s Director, Suzanne Lentzsch, MD, is the principal investigator of a number of amyloidosis-related clinical trials currently being conducted at Columbia/NewYork-Presbyterian and allowing our patients to benefit from emerging therapies. In addition she is the principle investigator of a multi-center trial in the Amyloidosis Network which includes five major medical centers in the United States. The researchers are studying the causes of systemic amyloidosis and considering ways to improve patient care. Preliminary results are very promising and enrollment is currently open.
Further our center offers a clinical trial using a monoclonal antibody 11-1F4 that is directly targeting the amyloid plaques and is the only center worldwide that offers this monoclonal antibody.